Head to Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) and Voyager Therapeutics (NASDAQ:VYGR)

Tarsus Pharmaceuticals (NASDAQ:TARS) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Tarsus Pharmaceuticals and Voyager Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-180.00%	-63.99%	-47.64%
Voyager Therapeutics	6.28%	3.31%	2.33%

Earnings & Valuation

This table compares Tarsus Pharmaceuticals and Voyager Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$83.37 million	16.74	-$135.89 million	($4.77)	-7.74
Voyager Therapeutics	$143.77 million	2.72	$132.33 million	($0.05)	-144.00

Voyager Therapeutics has higher revenue and earnings than Tarsus Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tarsus Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Institutional & Insider Ownership

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 4.5% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Tarsus Pharmaceuticals and Voyager Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	0	1	5	1	3.00
Voyager Therapeutics	0	1	5	0	2.83

Tarsus Pharmaceuticals currently has a consensus target price of $51.60, suggesting a potential upside of 39.08%. Voyager Therapeutics has a consensus target price of $17.83, suggesting a potential upside of 149.77%. Given Voyager Therapeutics’ higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Tarsus Pharmaceuticals.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.